Oxazinanes
Apexbio Technology LLC KN-93 hydrochloride 1956426-56-4 10mM (in 1mL DMSO)
KN-93 hydrochloride (CAS 1956426-56-4) is a selective inhibitor of Ca2 /calmodulin-dependent protein kinase II (CaMK II) binding competitively at the calmodulin site with a reported Ki of 0 37 M and an IC50 of 370 nM In isolated gastric parietal cells KN-93 suppresses acid secretion stimulated by carbachol and histamine with IC50 values of 0 15 M and 0 3 M respectively and inhibits mucin-stimulated aminopyrine uptake (IC50 0 6 M) Additionally KN-93 shows inhibitory activity against H /K -ATPase and directly blocks voltage-gated potassium (Kv) channels by promoting C-type inactivation KN-93 is widely used to probe CaMK II signaling and its downstream physiological effects in cellular and electrophysiological studies
Apexbio Technology LLC KN-93 hydrochloride 1956426-56-4 1mg
KN-93 hydrochloride (CAS 1956426-56-4) is a selective inhibitor of Ca2 /calmodulin-dependent protein kinase II (CaMK II) binding competitively at the calmodulin site with a reported Ki of 0 37 M and an IC50 of 370 nM In isolated gastric parietal cells KN-93 suppresses acid secretion stimulated by carbachol and histamine with IC50 values of 0 15 M and 0 3 M respectively and inhibits mucin-stimulated aminopyrine uptake (IC50 0 6 M) Additionally KN-93 shows inhibitory activity against H /K -ATPase and directly blocks voltage-gated potassium (Kv) channels by promoting C-type inactivation KN-93 is widely used to probe CaMK II signaling and its downstream physiological effects in cellular and electrophysiological studies
Apexbio Technology LLC CBL0137 (hydrochloride) 1197397-89-9 2mg
CBL0137 (hydrochloride) (CAS 1197397-89-9) is a small-molecule curaxin that modulates transcriptional regulation by targeting the Facilitates Chromatin Transcription (FACT) complex This interaction leads to activation of p53 (EC50 0 37 M) and inhibition of NF- B signaling (EC50 0 47 M) pathways commonly dysregulated in cancer In vitro CBL0137 induces apoptosis in pancreatic cancer cell lines affecting both differentiated tumor cells and cancer stem cells In vivo studies demonstrate antitumor activity in models resistant to gemcitabine with additional combinatory effects attributed to transcriptional inhibition CBL0137 is under clinical evaluation in solid and hematological malignancies